Prostratin (CAS 60857-08-1)

Prostratin is a Protein kinase C (PKC) activator that does not induce tumor formation. Prostratin upregulates latent HIV-1 provirus expression. Prostratin also inhibts HIV infection and viral spread at the entry/fusion step of viral life cycle. Prostratin essentially helps the body rid the latently infected CD4+ T-cells of the virus. Theoretically when used with other drugs (in vitro), Prostratin could eliminate the virus from latent and active life cycles completely. Prostratin is an activator of IKK. Prostratin was interestingly discovered from an ethnobotanical studies on Samoa. Prostratin was originally discovered in the tree Homolanthus nutans of which was known to be useful to scientific research on viruses.

Références

1. The structure of prostratin: A toxic tetracyclic diterpene ester from Pimelea prostrata.: A.R. Cashmore, et al.; Tetrahedron Lett. 20, 1737 (1976)
New tigliane and daphnane derivatives from Pimelea prostrata and Pimelea simplex: S. Zayed, et al.; Experientia 33, 1554 (1977)
2. Nonpromoting 12-deoxyphorbol 13-esters inhibit phorbol 12-myristate 13-acetate induced tumor promotion in CD-1 mouse skin: Z. Szallasi, et al.; Cancer Res. 53, 2507 (1993)
3. Prostratin antagonizes HIV latency by activating NF-kappaB: S.A. Williams, et al.; J. Biol. Chem. 279, 42008 (2004)
4. Prostratin as a new therapeutic agent targeting HIV viral reservoirs: M. Hezareh; Drug News Perspect. 18, 496 (2005), (Review)
5.Effects of prostratin on Cyclin T1/P-TEFb function and the gene expression profile in primary resting CD4+ T cells: T. L. Sung & A. P. Rice; Retrovirology 3, 66 (2006)